|
|
 |
Damavand, the highest Asian inactive volcano in the Alborz mountains, around 66 km in the northeastern Tehran, Iran (the highest elevation is 5,671 m) (Photo by M. H. Azizi MD, Winter 2015).
A winter view of Abali, around 57 km in the northeastern Tehran, Iran (Photo by M. H. Azizi MD, 2015).
|
|
|
|
|
|
|
|
|
The collection of articles appearing in the current book consists of manuscripts on the history of medicine in Iran, initially published from 1998 to 2014 in the “Archives of Iranian Medicine” (AIM). These articles are categorized into four separate parts, based on their subjects: Part 1) Ancient Times, Medieval Period, Part 2) Contemporary Medicine, Part 3) Outstanding Physicians and Part 4) Historical Background of Fatal Diseases in Iran. These 73 manuscripts have now been compiled in a 446 pages book for those who are interested in the history of Iranian medicine.more
Since the Archive of Iranian Medicine (AIM) journal presents as Open Access monthly, online periodical from May 2013, thus dear readers may refer to the journal website (www.aimjournal.ir) for free downloading of the published papers.
AIM Office
|
|
|
|
|
|
|
|
|
A Monthly Peer-Reviewed Medical Journal Published by the Academy of Medical Sciences of the I.R. Iran; Indexed in PubMed/MEDLINE, ISI Web of Science, EMBASE, SCOPUS, CINHAL, PASCAL, CSA, SID, ISSN: Print 1029-2977, Online 1735-3947.The impact factor of Archives of Iranian Medicine according to Journal Citation Reports®(JCR®) 2012 is 1.222.
|
|
|
|
|
Screening for Lynch Syndrome in Cases with Colorectal Carcinoma from Mashhad
1 |
|
Authors’ affiliations: 1Department of Gastroenterology and Hepatology, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran. 2Gastroenterology and hepatology research center, Mashhad University of Medical Sciences, Mashhad, Iran. 3Department of Pathology, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran. 4Pathology Department, Education and Research Department, Razavi hospital, Mashhad, Iran. 5Medical Student, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran. 6Division of Gastroenterology, Department of Internal Medicine, Rush University Medical Center, Chicago, Illinois, USA. 7Student Research Committee, Department of Medical Informatics, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran. 8MSC of biochemistry, Mashhad pathobiology lab, Mashhad, Iran. 9Hematology and Oncology Department, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran. 10PHD Student, Department of Biotechnology, Ferdowsi University of Mashhad, Mashhad, Iran. 11Radiology Department, Mashhad Branch, Islamic Azad University, Mashhad, Iran. 12Anatomical and Clinical Pathologist, Moayyed Medical Laboratory, Mashhad, Iran.
•Corresponding author and reprints: Kambiz Akhavan Rezayat, Division of Gastroenterology, Department of Internal Medicine, Mashhad University Medical sciences, Mashhad, Iran. Tel: +985138598818, Fax: +98513932481, E-mail: akhavanrk@mums.ac.ir
Accepted for publication: 12 April 2017
|
Download PDF Fulltext
|
|
Authors:
Ladan Goshayeshi1, Alireza Khooiee2, Kamran Ghaffarzadegan3, Mahla Rahmani Khorram4, Faraz Bishehsari5, Benyamin Hoseini6, *Kambiz Akhavan Rezayat7, Abbas Esmaeilzadeh8, Hooman Mosannen Mozaffari9, Omid Ghanayee10, Ali Bahari11, Abolghasem Allahyari12, Alireza Bari13, Azita Ganji14, Lena Goshayeshi15, Farnood Rajabzadeh16, Jaleh Esmaeili17,
|
|
|
|
Keywords:
Cancer screening, colorectal carcinoma, immunohistochemistry, Lynch syndrome, mismatch repair
|
|
INTRODUCTION: Lynch Syndrome (LS) is a genetically inherited autosomal disorder that increases the risk of many types of cancer, especially colorectal cancer (CRC). Identifying these subjects improves morbidity and mortality. We aimed to assess the prevalence of LS with both clinical criteria and universal strategy in Mashhad, Iran.
METHODS: In this retrospective study, we screened 322 patients with CRC between 2013 and 2016 in Mashhad, Iran. CRCs were screened based on Amsterdam II criteria, revised Bethesda guideline, and universal strategy. Information regarding the clinical criteria was obtained by interviewing the patients or, their families. Tumors were screened by pathologists with IHC staining of four Mismatch repair (MMR) proteins (MLH1, MSH2, MSH6, and PMS2). Tumors with absent IHC staining of MLH1 were tested for BRAF mutations to exclude sporadic CRCs.
RESULTS: Of 322 CRCs, 33 cases were found to be deficient-MMR; 22 of these had concurrent loss of MLH1 and PMS2, followed by concurrent loss of MSH2 and MSH6 in 8 CRCs. Twenty-two cases with a loss of MLH1 underwent testing for the BRAF mutation, 4 of which were recognized as a positive BRAF mutation. Finally, 29 CRCs were found as being positive screen for LS. Poor sensitivity (21.74%) was found for the Amsterdam II criteria and a poor positive predictive value (15.39%) for the revised Bethesda.
CONCLUSION: Application of clinical criteria may not be effective enough to identify LS and at least 2-antibody panel (PMS2, MSH6) should be conducted for newly diagnosed CRCs.
|
|
|
|
ISSN:1029-2977
Article type:Original
|
|
| |
|
|